Amivantamab, the first approved EGFR and MET bispecific antibody for treating locally advanced or metastatic NSCLC with EGFR exon 20 insertion (ex20ins) mutations, has garnered attention for its promising clinical prospects in recent years2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.